ライフサイエンスコーパス: RVFV

1 RVFV has a trisegmented single-stranded RNA (ssRNA) geno

2 RVFV has caused large, devastating periodic epizootics a

3 RVFV infection also elicited autophagy in mouse and huma

4 RVFV is a mosquito-borne bunyavirus that is endemic to A

5 RVFV is classified as a category A priority pathogen and

6 RVFV is listed as a select agent with significant potent

7 RVFV MP12-infected cells also displayed an S phase arres

8 RVFV NSm protein is the first identified Phlebovirus pro

9 RVFV virulence depends on the interferon antagonist non-

10 us challenge with the virulent Kenya-128B-15 RVFV strain.

11 In humans, 15 RVFV seroconversions were observed over 629 person-years

12 ulent Rift Valley fever virus strain ZH-501 (RVFV ZH-501) at 126 days after vaccination were protecte

13 A RVFV inhibition ELISA was used to screen 977 cattle, 1,5

14 interferon (IFN-alpha) in sera, accumulated RVFV antigens in dendritic cells at the local draining l

15 es or antiviral agents with activity against RVFV, and details of its life cycle and interaction with

16 the antiviral activity of IFN-alpha against RVFV.

17 Detection of antibodies against RVFV antigens assist in estimating exposure as antibodie

18 onoclonal antibody (mAb) combination against RVFV that is effective at minimal doses in a lethal mous

19 ro and protection efficacies in mice against RVFV infection, compared to the Gc-specific monoclonal a

20 tibody and provides solid protection against RVFV challenge in the most susceptible natural target sp

21 hAdOx1, to develop a vaccine for use against RVFV in both livestock and humans.

22 or treatment available for human use against RVFV.

23 is currently available for human use against RVFV.

24 sed rationale for designing vaccines against RVFV.

25 esent study determined the 3' termini of all RVFV mRNAs.

26 In the past 15 years alone, RVFV caused tens of thousands of human cases, hundreds o

27 We established an RVFV T7 RNA polymerase-driven minigenome system in which

28 Unexpectedly, the coexpression of an RVFV nonstructural protein, NSs, with N and L proteins r

29 The discrimination of WNV and RVFV antigen detection in mixed Raman spectra was achiev

30 nes and diagnostics, since no effective anti-RVFV treatments are available for human use.

31 ceptor adaptor, MyD88, was required for anti-RVFV autophagy, revealing an evolutionarily conserved re

32 whom 12.0% (158/1319) were positive for anti-RVFV immunoglobulin G (IgG).

33 ination resulted in a rapid increase in anti-RVFV IgM (day 4) and IgG (day 7) titers.

34 downregulate PKR with similar efficiency as RVFV, while infection with the other phleboviruses-i.e.,

35 s, indicating that these viruses, as well as RVFV on certain cell types, employ additional unidentifi

36 ressed RVFV N-based indirect ELISA to assess RVFV seroprevalence in livestock in areas of endemicity

37 ld-type infection, we utilized an attenuated RVFV lacking NSs to examine host responses following pri

38 to show that both pathogenic and attenuated RVFV strains require GAGs for efficient infection on som

39 munogenicity and efficacy of live-attenuated RVFV vaccine, which will lead to rational design of safe

40 Because RVFV cap-snatches in RNA granules, the increased level o

41 tion of the DNA damage signaling cascades by RVFV infection and found virally inducted phosphorylatio

42 compared to other disease outcomes caused by RVFV.

43 cellular factors, and entry pathways used by RVFV and other members of the family Bunyaviridae remain

44 Clinically, RVFV induces a gamut of symptoms ranging from febrile il

45 Consequently, RVFV replication was severely reduced in Skp1-depleted c

46 species were exposed to aerosols containing RVFV.

47 In contrast, RVFV infection levels in other tissues showed no differe

48 viral responses are critical for controlling RVFV replication, but the roles of downstream adaptive i

49 Knockdown of VCP resulted in decreased RVFV replication, reduced Gn Golgi complex localization,

50 ell lines were permissive for Lrp1-dependent RVFV infection.

51 Here, we demonstrate that field-deployable RVFV detection can provide reliable, sensitive, and spec

52 ility of the recombinant N antigen to detect RVFV antibody responses was evaluated in ELISA format us

53 ; in addition, the N-specific ELISA detected RVFV seroprevalence levels of 26.1% and 54.3% in indigen

54 T16 selectively degrades 5'-TOP mRNAs during RVFV infection and this decay is triggered in response t

55 ite this, translational arrest occurs during RVFV infection by unknown mechanisms.

56 re, we investigated the role of PABP1 during RVFV infection of HeLa cells.

57 t mortality and more subtle pathology during RVFV infection.

58 st that production of the NSs protein during RVFV infection leads to sequestration of PABP1 in the nu

59 HIV, and MHV68 and acutely pathogenic EBOV, RVFV, RSSEV, and Nipah viruses under BSL4 conditions.

60 ism of PKR by NSs is essential for efficient RVFV replication in mammalian cells.

61 nization with ChAdOx1-GnGc vaccine, encoding RVFV envelope glycoproteins, elicits high-titre RVFV-neu

62 ila DDX17 (Rm62) in cells and flies enhanced RVFV infection.

63 p62, forming nuclear filaments and enhancing RVFV virulence.

64 The estimated RVFV seroprevalence, adjusted for survey design, was 42.

65 using the recombinant baculovirus-expressed RVFV N-based indirect ELISA to assess RVFV seroprevalenc

66 However, at least filoviruses, RVFV, and CPXV are immune to its inhibitory effect.

67 428) phosphorylation was decreased following RVFV infection.

68 nalysis of the human host response following RVFV infection, which could give insight into novel host

69 In an effort to repurpose drugs for RVFV treatment, our previous studies screened a library

70 been firmly established as risk factors for RVFV exposure.

71 The implications of these findings for RVFV genome packaging and the potential to develop multi

72 of sorafenib, was found to be important for RVFV egress.

73 s (RVFV), thus providing an animal model for RVFV pathogenesis.

74 icial role of Wnt signaling was observed for RVFV, along with other disparate bunyaviruses, indicatin

75 The potential for RVFV introduction outside the area of endemicity highlig

76 To determine whether PABP1 was required for RVFV infection, we measured the production of nucleocaps

77 , indicating that PABP1 was not required for RVFV infection.

78 s used to identify host factors required for RVFV infection.

79 tible species, is an attractive strategy for RVFV.

80 sis and suggest that future therapeutics for RVFV hemorrhagic disease might target inhibition of cell

81 allenge protects the dams and offspring from RVFV infection.

82 hat binds Lrp1 weakly failed to protect from RVFV infection.

83 to the kinetics of antiviral protection from RVFV infection.

84 have recently reported novel next generation RVFV vaccines that are safe for use in pregnant and youn

85 However, RVFV NSs mRNA synthesis, but not N mRNA synthesis, was r

86 Human RVFV infections generally manifest as a self-limiting fe

87 tional design of safe and highly immunogenic RVFV vaccines for livestock and humans.

88 valuated the roles of B cells and T cells in RVFV pathogenesis.

89 e fundamental mechanisms of RNA packaging in RVFV would be valuable for the development of antivirals

90 s introduction of this virus could result in RVFV becoming endemic in North America.

91 with N protein, L protein, and viral RNAs in RVFV-infected cells.

92 between Gn and all the viral RNA segments in RVFV-infected cells.

93 An essential step in RVFV life cycle is the packaging of viral RNA segments t

94 Functional studies in RVFV-infected cells show that the OmegaXaV motif is requ

95 a shutoff of host cell protein synthesis in RVFV-infected cells.

96 niques and boiling of milk fully inactivates RVFV in milk.

97 but not the related helicase DDX5 increased RVFV replication in human cells.

98 e have addressed the stability of infectious RVFV in milk.

99 ackaging of these RNAs to produce infectious RVFV.

100 rmacologic activation of autophagy inhibited RVFV infection in mammalian cells, including primary hep

101 e cellular target of sorafenib that inhibits RVFV propagation, so that this information can be used a

102 Instead, RVFV was introduced through ruminant trade and subsequen

103 ining their efficiency of incorporation into RVFV particles.

104 profile of viral RNA segments packaged into RVFV particles showed that all three genomic RNA segment

105 e copackaging of the three genomic RNAs into RVFV particles.

106 esulted in the copackaging of both RNAs into RVFV-like particles, while replacing M RNA with M1 RNA,

107 of incorporation of viral RNA segments into RVFV particles.

108 In 2008 to 2009, a large RVFV outbreak was detected in Malagasy livestock and hum

109 Mice were protected from lethal RVFV challenge.

110 In Drosophila, Toll-7 limited RVFV replication and mortality through activation of aut

111 c pathogen that primarily affects livestock, RVFV can also cause lethal hemorrhagic fever and encepha

112 Administering mAb RVFV-268 2 h prior to RVFV challenge or 24 h post-challe

113 Here we show that mAb RVFV-268 reduces viral replication in rat placenta expla

114 he pathogenesis in humans and livestock make RVFV a serious public health concern.

115 heep and goat populations exposed to natural RVFV field infection in The Gambia.

116 AP(D3)) and anti-Lrp1 antibodies neutralizes RVFV infection in taxonomically diverse cell lines.

117 rtation from the East African mainland, nine RVFV whole genomic sequences were generated for viruses

118 The ability of RVFV to expand geographically outside sub-Saharan Africa

119 prevention of viremia, fever and absence of RVFV-associated histopathological lesions.

120 The intracellular accumulation of RVFV virions was also observed in cells transfected with

121 l models to study these important aspects of RVFV transmission are currently lacking.

122 netics system to rescue infectious clones of RVFV MP-12 strain entirely from cDNA, the first for any

123 A key component of RVFV virulence is its ability to form nuclear filaments

124 g strategy for the prevention and control of RVFV infections in susceptible hosts.

125 CD4(+) T cells are critical determinants of RVFV pathogenesis and play an important role in preventi

126 We identified a stable core domain of RVFV NSs (residues 83-248), and solved its crystal struc

127 Marmosets were susceptible to lower doses of RVFV than AGM.

128 ed towards the broader infection dynamics of RVFV, because suitable host, vector and environmental co

129 the thymidine kinase gene, and expression of RVFV glycoproteins, Gn and Gc.

130 nomic RNA, supported by the co-expression of RVFV N and L helper proteins.

131 NSs protein, a major virulence factor of RVFV, inhibits host transcription including interferon (

132 increase in both the range and frequency of RVFV outbreaks over the years, there is currently no vac

133 lar localization and biological functions of RVFV NSs, and the co-expression of truncated NSs does no

134 e-sense viruses, the segmented RNA genome of RVFV is encapsidated by a nucleocapsid protein (N).

135 A hallmark of RVFV pathology is NSs filament formation in infected cel

136 In addition we demonstrate induction of RVFV-neutralizing antibody by ChAdOx1-GnGc vaccination i

137 es developed mild fevers after inhalation of RVFV, but no other clinical signs were noted and no maca

138 gether suggest that the primary mechanism of RVFV MP-12 uptake is dynamin-dependent, caveolin-1-media

139 To determine the cellular entry mechanism of RVFV, we used small-molecule inhibitors, RNA interferenc

140 nce for the importance of oligomerization of RVFV L protein for its polymerase activity.

141 three-dimensional structural organization of RVFV vaccine strain MP-12 by cryoelectron tomography.

142 eplication in hepatocytes to pathogenesis of RVFV remains undefined.

143 aluated the infectivity and pathogenicity of RVFV in the common marmoset (Callithrix jacchus) by i.v.

144 ls of PABP1, we found that the percentage of RVFV N-positive cells was decreased in cell populations

145 We found that the overall percentage of RVFV N-positive cells was not changed by siRNA treatment

146 ticle aerosol challenge of 5 x 10(5) PFUs of RVFV ZH-501.

147 e and sex were not significant predictors of RVFV human exposure.

148 IMPORTANCE The prevention of RVFV encephalitis requires intact adaptive immunity.

149 rafenib are important for the propagation of RVFV.

150 IgG against the N protein of RVFV was detected through multiplex bead assay (MBA).

151 m by which sorafenib inhibits the release of RVFV virions from the cell.

152 e organization of G(C) in the outer shell of RVFV.

153 h viremias in livestock lead to spillover of RVFV into other anthrophillic vectors (Culex and Anophel

154 effective approach to prevent the spread of RVFV.

155 ort that an infection by the MP-12 strain of RVFV induces phosphorylation of the p65 component of the

156 decreased in cells infected with a strain of RVFV lacking the gene encoding the RVFV nonstructural pr

157 The crystal structure of RVFV G(C) reveals a class II fusion protein architecture

158 In our study, we report the structure of RVFV L protein at 3.6 A resolution by cryo-EM.

159 In our study, we report the structure of RVFV L protein at 3.6 angstrom resolution by cryo-EM.

160 s that RVFV is pleomorphic, the structure of RVFV MP-12 was found to be highly ordered.

161 The 1.93-A crystal structure of RVFV N and electron micrographs of ribonucleoprotein (RN

162 tion regarding the genetic subpopulations of RVFV and shows the genetic stability of the MP-12 vaccin

163 R vesicles.IMPORTANCE In humans, symptoms of RVFV infection mainly include a self-limiting febrile il

164 ver has been demonstrated as a key target of RVFV, the contribution of viral replication in hepatocyt

165 oietic cells are one of the major targets of RVFV in vivo; however, their contribution to RVFV pathog

166 Therefore, translation of RVFV mRNAs is compromised by multiple mechanisms during

167 mplications for fundamental understanding of RVFV virulence.

168 transcription, pointing to the uniqueness of RVFV NSs mRNA synthesis.

169 against ZH501, the fully virulent version of RVFV.

170 n be used to study the molecular virology of RVFV, assess current vaccine candidates, produce new vac

171 iruses were embedded within a large clade of RVFVs from the 2006-2007 outbreak in East Africa and sha

172 athrin-mediated endocytosis had no effect on RVFV infection.

173 cropinocytosis, had no significant impact on RVFV infection.

174 partially exerts its inhibitory influence on RVFV replication by interfering with IKK-beta2-mediated

175 MP-12 is the only RVFV strain excluded from the select-agent rule and hand

176 viral replication in hepatocytes to overall RVFV pathogenesis is less well defined.

177 12 is different from its parental pathogenic RVFV strain, strain ZH548, because of the presence of 23

178 Rift Valley fever phlebovirus (RVFV) is a clinically and economically important pathoge

179 Preventing RVFV infection of livestock by vaccination is a key elem

180 fficacy of the DeltaNSs-DeltaNSm recombinant RVFV (rRVFV) vaccine (which lacks the NSs and NSm virule

181 rus expression system to produce recombinant RVFV nucleoprotein (N) for use as serodiagnostic antigen

182 ess this issue, we developed two recombinant RVFV vaccines using vaccinia virus (VACV) as a vector fo

183 Expression of DN caveolin-1 also reduced RVFV infection significantly, while expression of DN EPS

184 caveolin-1 and dynamin, drastically reduced RVFV infection in multiple cell lines.

185 skeletal reorganization, resulted in reduced RVFV replication, indicating that this pathway is import

186 ling as an important host pathway regulating RVFV infection.

187 In response, RVFV inhibits two well-known antiviral pathways that att

188 IFITM-2 and -3 restricted RVFV infection mostly by preventing virus membrane fusio

189 onal arrest of 5'-TOPs via 4EBP1/2 restricts RVFV replication, and this increased RNA decay results i

190 which target the TATA binding protein (TBP), RVFV appears to target the basal transcription factor TH

191 In contrast to previous assertions that RVFV is pleomorphic, the structure of RVFV MP-12 was fou

192 lts presented in this study demonstrate that RVFV MP-12 possesses T=12 icosahedral symmetry and sugge

193 Here we provide evidence that RVFV strain MP-12 uses dynamin-dependent caveola-mediate

194 Here, we find that RVFV infection triggers the decay of core translation ma

195 Our finding that RVFV NSs protein augmented minigenome RNA synthesis was

196 With further investigation, we found that RVFV infection activated Wnt signaling, was enhanced whe

197 Unexpectedly, we found that RVFV NSs truncated at aa.

198 etic screening in human cells and found that RVFV utilizes glycosaminoglycans to attach to host cells

199 We found that RVFV was restricted by IFITM-2 and -3 but not by IFITM-1

200 These results indicate that RVFV NSs induces DNA damage signaling pathways that are

201 ese data are consistent with the notion that RVFV outbreaks in Madagascar result not from emergence f

202 Our data point to the possibility that RVFV infection may result in the generation of novel ver

203 al minigenome RNA synthesis, suggesting that RVFV NSs protein and Bunyamwera virus NSs protein have d

204 The RVFV M segment encodes the NSm and 78-kDa proteins and t

205 strain of RVFV lacking the gene encoding the RVFV nonstructural protein S (NSs).

206 for the transcription of mRNA expressing the RVFV virulence factor, NSs, displayed a significantly hi

207 In addition, these results show how the RVFV incorporates a simple motif into the NSs protein th

208 family, replication and transcription of the RVFV minigenome required expression of viral N and L pro

209 alculated using the Fourier transform of the RVFV MP-12 tomogram.

210 f a recombinant subunit vaccine based on the RVFV Gn and Gc glycoproteins.

211 s from a convalescent patient, targeting the RVFV envelope proteins Gn and Gc.

212 Consistent with the fact that the RVFV can be distinguished from other Bunyaviridae-family

213 These data suggest that the RVFV NSs protein is able to interact with the TFIIH subu

214 Infection of cells with the RVFV MP-12 vaccine strain reduced p62 protein levels to

215 e to the most recent common ancestor for the RVFVs.

216 V envelope glycoproteins, elicits high-titre RVFV-neutralizing antibody and provides solid protection

217 In contrast to RVFV, however, cellular transcription remains unaffected

218 RVFV in vivo; however, their contribution to RVFV pathogenesis remains poorly understood.

219 ernative route of protective immunization to RVFV in addition to conventional intramuscular injection

220 In addition, disruption of PTAR1 led to RVFV resistance as well as reduced heparan sulfate surfa

221 Administering mAb RVFV-268 2 h prior to RVFV challenge or 24 h post-challenge protects the dams

222 nalyze the host transcriptome in response to RVFV infection.

223 CD4(+) T cells regulate immune responses to RVFV infection.

224 ellular helicases in type I IFN responses to RVFV.

225 y 42 of gestation, when fetal sensitivity to RVFV vaccine-induced teratogenesis is highest.

226 signs were noted and no macaque succumbed to RVFV infection.

227 Marmosets were more susceptible to RVFV than rhesus macaques and experienced higher rates o

228 re are no FDA-approved therapeutics to treat RVFV infection, and thus, there is an urgent need to und

229 er development of therapeutics used to treat RVFV infection.

230 might be an effective strategy for treating RVFV infection, which lacks approved vaccines and therap

231 cted with two genetically distinct wild-type RVFV strains and sera from indigenous sheep and goat pop

232 Understanding RVFV-host interactions is imperative to the design of no

233 completely protected mice against a virulent RVFV challenge dose which was 100,000-fold greater than

234 lenged at day 122 of gestation with virulent RVFV (1.0 x 10(6) PFU intravenously).

235 ravenous and aerosol challenge with virulent RVFV in these macaques, which suggests further developme

236 Rift Valley fever virus (RVFV) (genus Phlebovirus, family Bunyaviridae) causes mo

237 Rift Valley fever virus (RVFV) (genus Phlebovirus, family Bunyaviridae) has a tri

238 Rift Valley fever virus (RVFV) (genus Phlebovirus, family Bunyaviridae) has a tri

239 viridae family) and Rift Valley fever virus (RVFV) (Phenuiviridae family).

240 ation of infectious Rift Valley fever virus (RVFV) and cowpox virus (CPXV) was also not affected by B

241 using the zoonotic Rift Valley fever virus (RVFV) and Schmallenberg virus (SBV), an emerging pathoge

242 Rift Valley fever virus (RVFV) causes major outbreaks among livestock, characteri

243 Rift Valley fever virus (RVFV) causes outbreaks of severe disease in people and l

244 Rift Valley fever virus (RVFV) causes recurrent insect-borne epizootics throughou

245 Rift Valley Fever virus (RVFV) causes recurrent outbreaks of acute life-threateni

246 Rift Valley fever virus (RVFV) has been expanding its geographical distribution w

247 Although the NSs of Rift Valley fever virus (RVFV) has been identified as an important virulence fact

248 increasing risk of Rift Valley fever virus (RVFV) infection as a global veterinary and public health

249 IMPORTANCE Rift Valley fever virus (RVFV) infection leads to eye damage in humans in up to 1

250 IMPORTANCE Rift Valley fever virus (RVFV) is a hemorrhagic fever virus that causes outbreaks

251 Rift Valley fever virus (RVFV) is a highly pathogenic arthropod-borne virus infec

252 Rift Valley fever virus (RVFV) is a member of the Bunyaviridae virus family (genu

253 Rift Valley fever virus (RVFV) is a member of the genus Phlebovirus within the fa

254 Rift Valley fever virus (RVFV) is a mosquito-borne human and veterinary pathogen

255 Rift Valley fever virus (RVFV) is a mosquito-borne pathogen that causes substanti

256 Rift Valley fever virus (RVFV) is a mosquito-borne zoonotic pathogen causing dise

257 Rift Valley fever virus (RVFV) is a negative-sense RNA virus (genus Phlebovirus,

258 Rift Valley fever virus (RVFV) is a single-stranded RNA virus capable of inducing

259 Rift Valley fever virus (RVFV) is a zoonotic pathogen capable of causing serious

260 Rift Valley fever virus (RVFV) is an arbovirus that is classified as a select age

261 Rift Valley fever virus (RVFV) is an arbovirus within the Bunyaviridae family cap

262 Rift Valley fever virus (RVFV) is an emerging pathogen that can cause severe dise

263 Rift Valley fever virus (RVFV) is an emerging RNA virus with devastating economic

264 human contact with Rift Valley Fever Virus (RVFV) is difficult to ascertain at a population level.

265 nalysis of purified Rift Valley fever virus (RVFV) particles demonstrated the presence of three negat

266 f Cell, report that Rift Valley Fever Virus (RVFV) targets cellular transcriptional apparatus to inhi

267 e highly infectious Rift Valley fever virus (RVFV) that can be lethal to humans and animals and resul

268 nly modulated local Rift Valley fever virus (RVFV) transmission in ruminants.

269 Rift Valley fever virus (RVFV), a member in the Phlebovirus genus of the family B

270 Rift Valley fever virus (RVFV), a mosquito-borne phlebovirus, has been detected i

271 ring infection with Rift Valley fever virus (RVFV), a mosquito-borne virus that causes disease in hum

272 DX17 in restricting Rift Valley fever virus (RVFV), a mosquito-transmitted virus in the bunyavirus fa

273 Rift Valley fever virus (RVFV), an ambisense member of the family Bunyaviridae, g

274 Rift Valley fever virus (RVFV), belonging to the genus Phlebovirus, family Bunyav

275 Rift Valley fever virus (RVFV), belongs to genus Phlebovirus of the family Bunyav

276 smitted bunyavirus, Rift Valley fever virus (RVFV), is a highly successful pathogen for which there a

277 e family, including Rift Valley fever virus (RVFV), La Crosse virus, Andes virus, and Hantaan virus,

278 Rift Valley fever virus (RVFV), like many other Bunyaviridae family members, is a

279 gic fever caused by Rift Valley fever virus (RVFV), thus providing an animal model for RVFV pathogene

280 ebolavirus (EBOV), Rift Valley fever virus (RVFV), Venezuelan equine encephalitis virus (VEEV), and

281 Rift Valley fever virus (RVFV), which belongs to the genus Phlebovirus, family Bu

282 nfections caused by Rift Valley fever virus (RVFV), which causes devastating disease in both humans a

283 ue virus (DENV) and Rift Valley fever virus (RVFV), which recently have seen significant progress in

284 ile virus (WNV) and Rift Valley fever virus (RVFV).

285 Rift Valley fever virus (RVFV, family Bunyaviridae, genus Phlebovirus) is a relev

286 Rift Valley fever virus (RVFV; family Bunyaviridae) is a clinically important, mo

287 Rift Valley fever virus (RVFV; family Bunyaviridae, genus Phlebovirus) has a trip

288 Rift Valley fever virus (RVFV; family Bunyaviridae, genus Phlebovirus) is an impo

289 RVF is caused by Rift Valley fever virus (RVFV; family Bunyaviridae, genus Phlebovirus), which has

290 tious viral disease caused by the RVF virus (RVFV) (Bunyaviridae: Phlebovirus), presents significant

291 rs associated with, antibodies to RVF virus (RVFV) in livestock in an area heavily affected by that o

292 IMPORTANCE The zoonosis RVF virus (RVFV) is one of the most serious arbovirus threats to bo

293 The causative agent, RVF virus (RVFV), can be naturally transmitted by mosquito, direct

294 Rift Valley fever (RVF) virus (RVFV) can cause severe human disease characterized by ei

295 nlike N of other negative-sense RNA viruses, RVFV N has no positively charged surface cleft for RNA b

296 zing antibody responses that correlated with RVFV clearance from peripheral tissues.

297 on upon co-expression in cells infected with RVFV.

298 e as useful models of aerosol infection with RVFV.

299 except for intact NSs does not interact with RVFV NSs even in the presence of intact C-terminus self-

300 e of NSs, were protected from wild-type (wt) RVFV challenge, while 72% of mice vaccinated with MP-12